Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Fly 28% But Investors Aren't Buying For Growth
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7.5
H.C. Wainwright analyst Ed Arce maintains $Akebia Therapeutics(AKBA.US)$ with a buy rating, and maintains the target price at $7.5.According to TipRanks data, the analyst has a success rate of 43.9%
Buy Rating Reaffirmed for Akebia Therapeutics Ahead of Vafseo's Market Launch
Express News | Akebia Therapeutics and U.S. Renal Care Initiate the Voice Trial of Vafseo® (Vadadustat) for Patients on Dialysis
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo (Vadadustat) for Patients on Dialysis
Express News | Akebia Therapeutics Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing